{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T17:38:22Z","timestamp":1794245902025,"version":"4.9.0"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T00:00:00Z","timestamp":1773705600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":44,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","award":["N42A680423"],"award-info":[{"award-number":["N42A680423"]}],"id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-44743-7","type":"journal-article","created":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T14:04:13Z","timestamp":1773756253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of microbiome-modulating strategies in cancer patients receiving immunotherapy (MSIT): A systematic review and meta-analysis"],"prefix":"10.1038","volume":"16","author":[{"given":"May Soe","family":"Thu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho Bao Chau","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Phuc","family":"Duc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van Hieu","family":"Mai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nattiya","family":"Hirankarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,17]]},"reference":[{"key":"44743_CR1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA. Cancer J. Clin. https:\/\/doi.org\/10.3322\/caac.21708 (2022).","journal-title":"CA. Cancer J. Clin."},{"issue":"1","key":"44743_CR2","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi, S., Yuan, R. & Engleman, E. G. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu. Rev. Pathol. 16 (1), 223\u2013249. https:\/\/doi.org\/10.1146\/annurev-pathol-042020-042741 (2021).","journal-title":"Annu. Rev. Pathol."},{"key":"44743_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14153575","author":"Y Lao","year":"2022","unstructured":"Lao, Y., Shen, D., Zhang, W., He, R. & Jiang, M. Immune checkpoint inhibitors in cancer therapy-how to overcome drug resistance?. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers14153575 (2022).","journal-title":"Cancers (Basel)"},{"key":"44743_CR4","doi-asserted-by":"publisher","first-page":"823618","DOI":"10.3389\/fimmu.2022.823618","volume":"13","author":"H Mamdani","year":"2022","unstructured":"Mamdani, H., Matosevic, S., Khalid, A. B., Durm, G. & Jalal, S. I. Immunotherapy in lung cancer: current landscape and future directions. Front. Immunol. 13, 823618. https:\/\/doi.org\/10.3389\/fimmu.2022.823618 (2022).","journal-title":"Front. Immunol."},{"issue":"5","key":"44743_CR5","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.3390\/ijms23052847","volume":"23","author":"P Dobosz","year":"2022","unstructured":"Dobosz, P., St\u0119pie\u0144, M., Golke, A. & Dzieci\u0105tkowski, T. Challenges of the immunotherapy: perspectives and limitations of the immune checkpoint inhibitor treatment. Int. J. Mol. Sci. 23 (5), 2847. https:\/\/doi.org\/10.3390\/ijms23052847 (2022).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"44743_CR6","doi-asserted-by":"publisher","first-page":"5154","DOI":"10.1038\/s41467-023-40745-5","volume":"14","author":"S Hiltbrunner","year":"2023","unstructured":"Hiltbrunner, S. et al. Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype. Nat. Commun. 14 (1), 5154. https:\/\/doi.org\/10.1038\/s41467-023-40745-5 (2023).","journal-title":"Nat. Commun."},{"issue":"2","key":"44743_CR7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40259-024-00700-2","volume":"39","author":"A Mariniello","year":"2025","unstructured":"Mariniello, A. et al. Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back. BioDrugs 39 (2), 215\u2013235. https:\/\/doi.org\/10.1007\/s40259-024-00700-2 (2025).","journal-title":"BioDrugs"},{"issue":"1","key":"44743_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13046-025-03313-x","volume":"44","author":"R He","year":"2025","unstructured":"He, R. et al. Dysbiosis and extraintestinal cancers. J. Experimental Clin. Cancer Res. 44 (1), 44. https:\/\/doi.org\/10.1186\/s13046-025-03313-x (2025).","journal-title":"J. Experimental Clin. Cancer Res."},{"issue":"1","key":"44743_CR9","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3390\/cancers17010090","volume":"17","author":"S Kumari","year":"2025","unstructured":"Kumari, S., Srilatha, M. & Nagaraju, G. P. Effect of Gut Dysbiosis on Onset of GI Cancers. Cancers 17 (1), 90 (2025). https:\/\/www.mdpi.com\/2072-6694\/17\/1\/90","journal-title":"Cancers"},{"issue":"3","key":"44743_CR10","doi-asserted-by":"publisher","first-page":"178","DOI":"10.14740\/wjon1587","volume":"14","author":"J Sarkar","year":"2023","unstructured":"Sarkar, J. et al. Fluctuations in gut microbiome composition during immune checkpoint inhibitor therapy. World J. Oncol. 14 (3), 178. https:\/\/doi.org\/10.14740\/wjon1587 (2023).","journal-title":"World J. Oncol."},{"issue":"6","key":"44743_CR11","doi-asserted-by":"publisher","first-page":"R257","DOI":"10.1016\/j.cub.2022.02.023","volume":"32","author":"GA Kuziel","year":"2022","unstructured":"Kuziel, G. A. & Rakoff-Nahoum, S. The gut microbiome. Curr. Biol. 32(6), R257\u2013R64. https:\/\/doi.org\/10.1016\/j.cub.2022.02.023 (2022).","journal-title":"Curr. Biol."},{"issue":"1","key":"44743_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01541-w","volume":"17","author":"Z Li","year":"2024","unstructured":"Li, Z. et al. Critical role of the gut microbiota in immune responses and cancer immunotherapy. J. Hematol. Oncol. 17(1), 33. https:\/\/doi.org\/10.1186\/s13045-024-01541-w (2024).","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"44743_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines13081807","volume":"13","author":"E Bretto","year":"2025","unstructured":"Bretto, E., Urp\u00ec-Ferreruela, M., Casanova, G. R. & Gonz\u00e1lez-Su\u00e1rez, B. The role of gut microbiota in gastrointestinal immune homeostasis and inflammation: Implications for inflammatory bowel disease. Biomedicines 13(8), 1807 (2025).","journal-title":"Biomedicines"},{"issue":"2","key":"44743_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11739-023-03374-w","volume":"19","author":"F Di Vincenzo","year":"2024","unstructured":"Di Vincenzo, F., Del Gaudio, A., Petito, V., Lopetuso, L. R. & Scaldaferri, F. Gut microbiota, intestinal permeability, and systemic inflammation: A narrative review. Intern. Emerg. Med. 19(2), 275\u201393. https:\/\/doi.org\/10.1007\/s11739-023-03374-w (2024).","journal-title":"Intern. Emerg. Med."},{"key":"44743_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2019.100772","author":"M Hagihara","year":"2020","unstructured":"Hagihara, M. et al. Clostridium butyricum modulates the microbiome to protect intestinal barrier function in mice with antibiotic-induced dysbiosis. Iscience https:\/\/doi.org\/10.1016\/j.isci.2019.100772 (2020).","journal-title":"Iscience"},{"key":"44743_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.iotech.2020.11.001","volume":"8","author":"C Soto Chervin","year":"2020","unstructured":"Soto Chervin, C. & Gajewski, T. F. Microbiome-based interventions: Therapeutic strategies in cancer immunotherapy. Immuno-Oncol. Technol. 8, 12\u201320. https:\/\/doi.org\/10.1016\/j.iotech.2020.11.001 (2020).","journal-title":"Immuno-Oncol. Technol."},{"issue":"5","key":"44743_CR17","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.jcmgh.2021.02.007","volume":"11","author":"S Ghosh","year":"2021","unstructured":"Ghosh, S., Whitley, C. S., Haribabu, B. & Jala, V. R. Regulation of intestinal barrier function by microbial metabolites. Cell. Mol. Gastroenterol. Hepatol. 11(5), 1463\u201382. https:\/\/doi.org\/10.1016\/j.jcmgh.2021.02.007 (2021).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"13","key":"44743_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202413197","volume":"12","author":"S Hou","year":"2025","unstructured":"Hou, S., Yu, J., Li, Y., Zhao, D. & Zhang, Z. Advances in fecal microbiota transplantation for gut dysbiosis-related diseases. Adv. Sci. 12(13), 2413197. https:\/\/doi.org\/10.1002\/advs.202413197 (2025).","journal-title":"Adv. Sci."},{"key":"44743_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2023.103038","volume":"141","author":"R Yang","year":"2023","unstructured":"Yang, R., Chen, Z. & Cai, J. Fecal microbiota transplantation: Emerging applications in autoimmune diseases. J. Autoimmun. 141, 103038. https:\/\/doi.org\/10.1016\/j.jaut.2023.103038 (2023).","journal-title":"J. Autoimmun."},{"issue":"1","key":"44743_CR20","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s40164-023-00442-x","volume":"12","author":"M Zhang","year":"2023","unstructured":"Zhang, M., Liu, J. & Xia, Q. Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target. Experimental Hematol. Oncol. 12 (1), 84. https:\/\/doi.org\/10.1186\/s40164-023-00442-x (2023).","journal-title":"Experimental Hematol. Oncol."},{"issue":"11","key":"44743_CR21","doi-asserted-by":"publisher","first-page":"3655","DOI":"10.1128\/AEM.04050-14","volume":"81","author":"J Reunanen","year":"2015","unstructured":"Reunanen, J. et al. Akkermansia muciniphila Adheres to Enterocytes and Strengthens the Integrity of the Epithelial Cell Layer. Appl. Environ. Microbiol. 81 (11), 3655\u20133662. https:\/\/doi.org\/10.1128\/AEM.04050-14 (2015).","journal-title":"Appl. Environ. Microbiol."},{"key":"44743_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00645","volume":"11","author":"J Ouyang","year":"2020","unstructured":"Ouyang, J. et al. The bacterium Akkermansia muciniphila: A sentinel for gut permeability and its relevance to HIV-related inflammation. Front. Immunol. 11-2020. https:\/\/doi.org\/10.3389\/fimmu.2020.00645 (2020).","journal-title":"Front. Immunol."},{"issue":"6371","key":"44743_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359 (6371), 91\u201397. https:\/\/doi.org\/10.1126\/science.aan3706 (2018).","journal-title":"Science"},{"issue":"6529","key":"44743_CR24","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1126\/science.abb5920","volume":"371","author":"EN Baruch","year":"2021","unstructured":"Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371 (6529), 602\u2013609. https:\/\/doi.org\/10.1126\/science.abb5920 (2021).","journal-title":"Science"},{"issue":"6529","key":"44743_CR25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1126\/science.abf3363","volume":"371","author":"D Davar","year":"2021","unstructured":"Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371 (6529), 595\u2013602. https:\/\/doi.org\/10.1126\/science.abf3363 (2021).","journal-title":"Science"},{"key":"44743_CR26","doi-asserted-by":"publisher","DOI":"10.1177\/17562848251327167","author":"C Gu","year":"2025","unstructured":"Gu, C. et al. Therapeutic potential of fecal microbiota transplantation in colorectal cancer based on gut microbiota regulation: From pathogenesis to efficacy. Therap Adv Gastroenterol https:\/\/doi.org\/10.1177\/17562848251327167 (2025).","journal-title":"Therap Adv Gastroenterol"},{"issue":"1","key":"44743_CR27","doi-asserted-by":"publisher","first-page":"2341717","DOI":"10.1080\/19490976.2024.2341717","volume":"16","author":"S Jiang","year":"2024","unstructured":"Jiang, S. et al. An emerging strategy: probiotics enhance the effectiveness of tumor immunotherapy via mediating the gut microbiome. Gut Microbes. 16 (1), 2341717. https:\/\/doi.org\/10.1080\/19490976.2024.2341717 (2024).","journal-title":"Gut Microbes"},{"issue":"11","key":"44743_CR28","doi-asserted-by":"publisher","first-page":"6022","DOI":"10.3390\/ijms25116022","volume":"25","author":"P Chandrasekaran","year":"2024","unstructured":"Chandrasekaran, P., Weiskirchen, S. & Weiskirchen, R. Effects of Probiotics on Gut Microbiota: An Overview. Int. J. Mol. Sci. 25 (11), 6022 (2024). https:\/\/www.mdpi.com\/1422-0067\/25\/11\/6022","journal-title":"Int. J. Mol. Sci."},{"key":"44743_CR29","doi-asserted-by":"publisher","first-page":"100096","DOI":"10.1016\/j.microb.2024.100096","volume":"4","author":"A Rowaiye","year":"2024","unstructured":"Rowaiye, A. et al. Gut microbiota alteration - Cancer relationships and synbiotic roles in cancer therapies. Microbe 4, 100096. https:\/\/doi.org\/10.1016\/j.microb.2024.100096 (2024).","journal-title":"Microbe"},{"key":"44743_CR30","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3332\/ecancer.2018.869","volume":"12","author":"AJ Scott","year":"2018","unstructured":"Scott, A. J., Merrifield, C. A., Younes, J. A. & Pekelharing, E. P. Pre-, pro- and synbiotics in cancer prevention and treatment-a review of basic and clinical research. Ecancermedicalscience 12, 869. https:\/\/doi.org\/10.3332\/ecancer.2018.869 (2018).","journal-title":"Ecancermedicalscience"},{"issue":"7","key":"44743_CR31","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.3390\/nu15071759","volume":"15","author":"NK Singh","year":"2023","unstructured":"Singh, N. K. et al. Synbiotics as Supplemental Therapy for the Alleviation of Chemotherapy-Associated Symptoms in Patients with Solid Tumours. Nutrients 15 (7), 1759 (2023). https:\/\/www.mdpi.com\/2072-6643\/15\/7\/1759","journal-title":"Nutrients"},{"issue":"1","key":"44743_CR32","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/j.foodchem.2011.11.016","volume":"132","author":"CH Huang","year":"2012","unstructured":"Huang, C. H., Cheng, J. Y., Deng, M. C., Chou, C. H. & Jan, T. R. Prebiotic effect of diosgenin, an immunoactive steroidal sapogenin of the Chinese yam. Food Chem. 132 (1), 428\u2013432. https:\/\/doi.org\/10.1016\/j.foodchem.2011.11.016 (2012).","journal-title":"Food Chem."},{"issue":"10","key":"44743_CR33","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/s41419-018-1099-3","volume":"9","author":"M Dong","year":"2018","unstructured":"Dong, M. et al. Diosgenin promotes antitumor immunity and PD-1 antibody efficacy against melanoma by regulating intestinal microbiota. Cell. Death Dis. 9 (10), 1039. https:\/\/doi.org\/10.1038\/s41419-018-1099-3 (2018).","journal-title":"Cell. Death Dis."},{"key":"44743_CR34","doi-asserted-by":"publisher","first-page":"106450","DOI":"10.1016\/j.fbio.2025.106450","volume":"68","author":"J Zhang","year":"2025","unstructured":"Zhang, J., Ma, X., Du, W., Mu, G. & Wu, X. Immune restoration mechanism analysis of Akkermansia PROBIO in mice treated with cyclophosphamide through Re-balancing microbiota composition. Food Bioscience. 68, 106450. https:\/\/doi.org\/10.1016\/j.fbio.2025.106450 (2025).","journal-title":"Food Bioscience"},{"issue":"4","key":"44743_CR35","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/s41591-022-01723-4","volume":"28","author":"L Derosa","year":"2022","unstructured":"Derosa, L. & Zitvogel, L. A probiotic supplement boosts response to cancer immunotherapy. Nat. Med. 28 (4), 633\u2013634. https:\/\/doi.org\/10.1038\/s41591-022-01723-4 (2022).","journal-title":"Nat. Med."},{"key":"44743_CR36","doi-asserted-by":"publisher","first-page":"104533","DOI":"10.1016\/j.ebiom.2023.104533","volume":"91","author":"G Gao","year":"2023","unstructured":"Gao, G. et al. Lacticaseibacillus rhamnosus Probio-M9 enhanced the antitumor response to anti-PD-1 therapy by modulating intestinal metabolites. EBioMedicine 91, 104533. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104533 (2023).","journal-title":"EBioMedicine"},{"issue":"10","key":"44743_CR37","doi-asserted-by":"publisher","first-page":"7355","DOI":"10.1007\/s00432-023-04656-8","volume":"149","author":"A Bhatt","year":"2023","unstructured":"Bhatt, A., Haslam, A. & Prasad, V. The effect of gastrointestinal microbiome supplementation on immune checkpoint inhibitor immunotherapy: a systematic review. J. Cancer Res. Clin. Oncol. 149 (10), 7355\u20137362. https:\/\/doi.org\/10.1007\/s00432-023-04656-8 (2023).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"44743_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1538969","volume":"16","author":"S Zhao","year":"2025","unstructured":"Zhao, S. et al. Assessing the impact of probiotics on immunotherapy effectiveness and antibiotic-mediated resistance in cancer: A systematic review and meta-analysis. Front. Immunol. 16, 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1538969 (2025).","journal-title":"Front. Immunol."},{"key":"44743_CR39","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372, n160. https:\/\/doi.org\/10.1136\/bmj.n160 (2021).","journal-title":"BMJ"},{"key":"44743_CR40","unstructured":"Higgins, J. P. T. et al. (eds) C,. Cochrane Handbook for Systematic Reviews of Interventions. version 5.2.0 (updated June (2017). https:\/\/training.cochrane.org\/handbook: Cochrane; 2017."},{"issue":"9","key":"44743_CR41","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","volume":"73","author":"K Slim","year":"2003","unstructured":"Slim, K. et al. Methodological index for non-randomized studies (minors): Development and validation of a new instrument. ANZ J. Surg. 73(9), 712\u20136. https:\/\/doi.org\/10.1046\/j.1445-2197.2003.02748.x (2003).","journal-title":"ANZ J. Surg."},{"issue":"1","key":"44743_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01381-z","volume":"21","author":"TH Barker","year":"2021","unstructured":"Barker, T. H. et al. Conducting proportional meta-analysis in different types of systematic reviews: A guide for synthesisers of evidence. BMC Med. Res. Methodol. 21(1), 189. https:\/\/doi.org\/10.1186\/s12874-021-01381-z (2021).","journal-title":"BMC Med. Res. Methodol."},{"issue":"4","key":"44743_CR43","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jspi.2009.09.017","volume":"140","author":"D Jackson","year":"2010","unstructured":"Jackson, D., Bowden, J. & Baker, R. How does the DerSimonian and Laird procedure for random effects meta-analysis compare with its more efficient but harder to compute counterparts?. J. Stat. Plan. Inference 140(4), 961\u201370. https:\/\/doi.org\/10.1016\/j.jspi.2009.09.017 (2010).","journal-title":"J. Stat. Plan. Inference"},{"issue":"4","key":"44743_CR44","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi, S., R\u00fccker, G. & Schwarzer, G. How to perform a meta-analysis with R: A practical tutorial. Evid. Based Ment. Health. 22(4), 153\u201360. https:\/\/doi.org\/10.1136\/ebmental-2019-300117 (2019).","journal-title":"Evid. Based Ment. Health."},{"issue":"7","key":"44743_CR45","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13524","volume":"51","author":"FM Al Amer","year":"2021","unstructured":"Al Amer, F. M. & Lin, L. Empirical assessment of prediction intervals in Cochrane meta-analyses. Eur. J. Clin. Invest. 51(7), e13524. https:\/\/doi.org\/10.1111\/eci.13524 (2021).","journal-title":"Eur. J. Clin. Invest."},{"issue":"1","key":"44743_CR46","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/pcmr.12738","volume":"32","author":"EN Baruch","year":"2019","unstructured":"Baruch, E. N. et al. Preliminary results from a microbiome-based phase i clinical trial - Fecal microbiota transplantation in metastatic melanoma patients who failed immunotherapy (NCT03353402). Pigment Cell. Melanoma Res. 32 (1), 97\u201398. https:\/\/doi.org\/10.1111\/pcmr.12738 (2019).","journal-title":"Pigment Cell. Melanoma Res."},{"key":"44743_CR47","doi-asserted-by":"publisher","first-page":"A1422","DOI":"10.1136\/jitc-2024-SITC2024.1266","volume":"12","author":"EN Baruch","year":"2024","unstructured":"Baruch, E. N. et al. The gut microbiome enhances anti-PD-1 efficacy in a tumor-agnostic manner: results from a phase II trial of fecal microbiota transplantation and anti-PD-1 re-induction in MSI-H refractory cancers. J. Immunother. Cancer. 12, A1422. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.1266 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"44743_CR48","doi-asserted-by":"publisher","unstructured":"Baruch, E. N. et al. Fecal microbiota transplantation (FMT) and re-induction of anti-PD-1 therapy in refractory metastatic melanoma patients - Preliminary results from a phase I clinical trial (NCT03353402). Cancer Res. 79 (13). https:\/\/doi.org\/10.1158\/1538-7445.SABCS18-CT042 (2019).","DOI":"10.1158\/1538-7445.SABCS18-CT042"},{"key":"44743_CR49","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.3233\/KCA-200001","volume":"4","author":"P Bergerot","year":"2020","unstructured":"Bergerot, P. et al. Pilot study to evaluate the biologic effect of the probiotic CBM588 in combination with nivolumab\/ ipilimumab for patients with mRCC. Kidney Cancer. 4, S45. https:\/\/doi.org\/10.3233\/KCA-200001 (2020).","journal-title":"Kidney Cancer"},{"key":"44743_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2320","author":"C Ciccarese","year":"2024","unstructured":"Ciccarese, C. et al. Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial. Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.2320 (2024).","journal-title":"Ann. Oncol."},{"key":"44743_CR51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.5078","author":"N Dizman","year":"2020","unstructured":"Dizman, N. et al. Randomized prospective trial assessing Bifidobacteriumcontaining probiotic supplementation in metastatic renal cell carcinoma (mRCC) patients receiving vascular endothelial growth factor-tyrosine kinase inhibitors (VEGF-TKIs). J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2020.38.15_suppl.5078 (2020).","journal-title":"J. Clin. Oncol."},{"key":"44743_CR52","doi-asserted-by":"publisher","unstructured":"Duttagupta, S. et al. Phase II trial of fecal microbiota transplantation in combination with ipilimumab and nivolumab in patients with advanced cutaneous melanoma (FMT-LUMINate trial). Cancer Res. 84 (7). https:\/\/doi.org\/10.1158\/1538-7445.AM2024-CT258 (2024).","DOI":"10.1158\/1538-7445.AM2024-CT258"},{"key":"44743_CR53","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1126","author":"A Elkrief","year":"2024","unstructured":"Elkrief, A. et al. Phase II trial of fecal microbiota transplantation (FMT) plus immune checkpoint inhibition (ICI) in advanced non-small cell lung cancer and cutaneous melanoma (FMT-LUMINate). Ann. Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2024.08.1126 (2024).","journal-title":"Ann. Oncol."},{"key":"44743_CR54","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e24148","author":"IRG Espinoza","year":"2024","unstructured":"Espinoza, I. R. G. et al. Effect of probiotics on quality of life for patients with cancer undergoing immunotherapy. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e24148 (2024).","journal-title":"J. Clin. Oncol."},{"key":"44743_CR55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4553","author":"R Fernandes","year":"2022","unstructured":"Fernandes, R. et al. Preventing adverse events in patients with renal cell carcinoma treated with doublet immunotherapy using fecal microbiota transplantation (FMT): Initial results from perform a phase I study. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.4553 (2022).","journal-title":"J. Clin. Oncol."},{"key":"44743_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2009","volume":"34","author":"D Galizia","year":"2023","unstructured":"Galizia, D. et al. 863P Microbiota and cytokines profile in patients (pts) affected by recurrent metastatic head and neck squamous cell carcinoma (R\/M HNSCC) treated with immune checkpoint inhibitors (ICIs) +\/- chemotherapy (CT) and prebiotic inulin in the PRINCESS study. Ann. Oncol. 34, S560. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2009 (2023).","journal-title":"Ann. Oncol."},{"key":"44743_CR57","doi-asserted-by":"crossref","unstructured":"Huang, M. J. et al. Fecal Microbiota Transplantation Plus Rechallenging Immunotherapy in Patients with Advanced Non Small Cell Lung Cancer: An Exploratory Study. pp. S262\u2013S3. (2024).","DOI":"10.1016\/j.jtho.2024.09.472"},{"issue":"8","key":"44743_CR58","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.chom.2024.06.010","volume":"32","author":"Y Kim","year":"2024","unstructured":"Kim, Y. et al. Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. Cell Host Microbe 32(8), 1380\u201393.e9. https:\/\/doi.org\/10.1016\/j.chom.2024.06.010 (2024).","journal-title":"Cell Host Microbe"},{"issue":"1","key":"44743_CR59","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/pcmr.13018","volume":"35","author":"JG Lenehan","year":"2022","unstructured":"Lenehan, J. G. et al. Combining Fecal Microbiota Transplantation with Immunotherapy in Treatment-Naive Patients with Advanced Melanoma. Pigment Cell. Melanoma Res. 35 (1), 139\u2013140. https:\/\/doi.org\/10.1111\/pcmr.13018 (2022).","journal-title":"Pigment Cell. Melanoma Res."},{"key":"44743_CR60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.6_suppl.374","author":"LA Meza","year":"2022","unstructured":"Meza, L. A. et al. Intestinal microbiome associated with development of grade 3\/4 adverse in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab plus ipilimumab (N\/I) and probiotic support: Results from a phase Ib study. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2022.40.6_suppl.374 (2022).","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"44743_CR61","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1002\/ijc.34842","volume":"154","author":"A Morita","year":"2024","unstructured":"Morita, A. et al. Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer. Int. J. Cancer. 154(9), 1607\u201315. https:\/\/doi.org\/10.1002\/ijc.34842 (2024).","journal-title":"Int. J. Cancer."},{"issue":"12","key":"44743_CR62","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1007\/s10147-024-02622-z","volume":"29","author":"H Nakatsukasa","year":"2024","unstructured":"Nakatsukasa, H. et al. Clinical impact of concomitant BIO-three use in advanced or recurrent non-small cell lung cancer treated with immune-checkpoint inhibitor. Int. J. Clin. Oncol. 29(12), 1840\u20139. https:\/\/doi.org\/10.1007\/s10147-024-02622-z (2024).","journal-title":"Int. J. Clin. Oncol."},{"issue":"16","key":"44743_CR63","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.105","volume":"41","author":"SR Park","year":"2023","unstructured":"Park, S. R. et al. Fecal microbiota transplantation combined with anti-PD-1 inhibitor for unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor. J. Clin. Oncol. 41(16), 105. https:\/\/doi.org\/10.1200\/jco.2023.41.16_suppl.105 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"44743_CR64","doi-asserted-by":"publisher","first-page":"e479","DOI":"10.1055\/s-0044-1786886","volume":"62","author":"K Pomej","year":"2024","unstructured":"Pomej, K. et al. Fecal microbiota transplant combined with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma who progressed on atezolizumab plus bevacizumab - interim analysis of the FAB-HCC phase II pilot study. Z. Gastroenterol. 62 (5), e479\u2013e80. https:\/\/doi.org\/10.1055\/s-0044-1786886 (2024).","journal-title":"Z. Gastroenterol."},{"key":"44743_CR65","doi-asserted-by":"publisher","first-page":"A645","DOI":"10.1136\/jitc-2022-SITC2022.0614","volume":"10","author":"B Routy","year":"2022","unstructured":"Routy, B. et al. Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients. J. Immunother. Cancer. 10, A645. https:\/\/doi.org\/10.1136\/jitc-2022-SITC2022.0614 (2022).","journal-title":"J. Immunother. Cancer"},{"issue":"8","key":"44743_CR66","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-023-02453-x","volume":"29","author":"B Routy","year":"2023","unstructured":"Routy, B. et al. Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: A phase I trial. Nat. Med. 29(8), 2121\u201332. https:\/\/doi.org\/10.1038\/s41591-023-02453-x (2023).","journal-title":"Nat. Med."},{"issue":"6575","key":"44743_CR67","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1126\/science.aaz7015","volume":"374","author":"CN Spencer","year":"2021","unstructured":"Spencer, C. N. et al. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science 374(6575), 1632\u201340. https:\/\/doi.org\/10.1126\/science.aaz7015 (2021).","journal-title":"Science"},{"issue":"6","key":"44743_CR68","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.annonc.2023.02.011","volume":"34","author":"A Spreafico","year":"2023","unstructured":"Spreafico, A. et al. First-in-class microbial ecosystem therapeutic 4 (MET4) in combination with immune checkpoint inhibitors in patients with advanced solid tumors (MET4-IO trial). Ann. Oncol. 34(6), 520\u201330. https:\/\/doi.org\/10.1016\/j.annonc.2023.02.011 (2023).","journal-title":"Ann. Oncol."},{"issue":"10","key":"44743_CR69","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/2326-6066.CIR-20-0051","volume":"8","author":"Y Tomita","year":"2020","unstructured":"Tomita, Y. et al. Association of probiotic Clostridium butyricum therapy with survival and response to immune checkpoint blockade in patients with lung cancer. Cancer Immunol. Res. 8(10), 1236\u201342. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0051 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"44743_CR70","doi-asserted-by":"publisher","DOI":"10.1177\/10732748241253959","author":"L Tong","year":"2024","unstructured":"Tong, L. et al. Evaluating Oral Probiotic Supplements as Complementary Treatment in Advanced Lung Cancer Patients Receiving ICIs: A Prospective Real-World Study. Cancer Control https:\/\/doi.org\/10.1177\/10732748241253959 (2024).","journal-title":"Cancer Control"},{"key":"44743_CR71","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-SITC2024.0669","volume":"12","author":"A Ullern","year":"2024","unstructured":"Ullern, A. et al. MITRIC: Microbiota transplant to cancer patients progressing on immunotherapy using feces from clinical responders. J. Immunother. Cancer 12, A767. https:\/\/doi.org\/10.1136\/jitc-2024-SITC2024.0669 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"44743_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-025-03604-9","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Effect of probiotics combined with immune checkpoint suppressors and chemotherapeutic agents on digestive system function, intestinal immunity and prognosis in patients with metastatic colorectal carcinoma: A quasi-experimental study. BMC Gastroenterol. https:\/\/doi.org\/10.1186\/s12876-025-03604-9 (2025).","journal-title":"BMC Gastroenterol."},{"issue":"3","key":"44743_CR73","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1007\/s12029-024-01095-7","volume":"55","author":"Y Wang","year":"2024","unstructured":"Wang, Y. et al. Concomitant medications alter clinical outcomes in patients with advanced digestive tract cancer receiving PD-1 checkpoint inhibitors combined with antiangiogenetic agents. J. Gastrointest. Cancer 55(3), 1388\u2013400. https:\/\/doi.org\/10.1007\/s12029-024-01095-7 (2024).","journal-title":"J. Gastrointest. Cancer"},{"key":"44743_CR74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2646","author":"Y Xue","year":"2024","unstructured":"Xue, Y. et al. Fecal microbiota transplantation combined with anti-PD-(L)1 inhibitors as first-line maintenance therapy for advanced gastric and non small cell lung cancer. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.2646 (2024).","journal-title":"J. Clin. Oncol."},{"key":"44743_CR75","doi-asserted-by":"crossref","unstructured":"Zhang, Y. et al. Fecal microbiota transplantation promotes immunotherapy sensitivity in refractory gastrointestinal cancer patients: open label, single-arm, single center, phase 1 study. (2024).","DOI":"10.1101\/2024.08.21.24312340"},{"key":"44743_CR76","doi-asserted-by":"publisher","unstructured":"Zhao, W. & Chen, Y. Fecal microbiota transplantation in combination with fruquintinib and tislelizumab in refractory microsatellite stable metastatic colorectal cancer: A single center phase II trial. Immuno-Oncology Technol. 16 https:\/\/doi.org\/10.1016\/j.iotech.2022.100214 (2022).","DOI":"10.1016\/j.iotech.2022.100214"},{"issue":"11","key":"44743_CR77","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.62347\/XKUJ3012","volume":"14","author":"W Zhao","year":"2024","unstructured":"Zhao, W. et al. Updated outcomes and exploratory analysis of RENMIN-215: Tislelizumab plus fruquintinib and fecal microbiota transplantation in refractory microsatellite stable metastatic colorectal cancer. Am. J. Cancer Res. 14(11), 5351\u201364. https:\/\/doi.org\/10.62347\/XKUJ3012 (2024).","journal-title":"Am. J. Cancer Res."},{"key":"44743_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102315","author":"W Zhao","year":"2023","unstructured":"Zhao, W. et al. Fecal microbiota transplantation plus tislelizumab and fruquintinib in refractory microsatellite stable metastatic colorectal cancer: An open-label, single-arm, phase II trial (RENMIN-215). eClinicalMedicine https:\/\/doi.org\/10.1016\/j.eclinm.2023.102315 (2023).","journal-title":"eClinicalMedicine"},{"key":"44743_CR79","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e14622","author":"W Zhu","year":"2024","unstructured":"Zhu, W. et al. Safety and preliminary efficacy of different doses of fecal microbiota capsule transplantation combined with anti-PD-1 inhibitor for patients with advanced malignant solid tumors. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e14622 (2024).","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"44743_CR80","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/s41591-022-01694-6","volume":"28","author":"N Dizman","year":"2022","unstructured":"Dizman, N. et al. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: A randomized phase 1 trial. Nat. Med. 28(4), 704\u201312. https:\/\/doi.org\/10.1038\/s41591-022-01694-6 (2022).","journal-title":"Nat. Med."},{"key":"44743_CR81","doi-asserted-by":"publisher","DOI":"10.1101\/2024.08.21.24312340","author":"Y Zhang","year":"2024","unstructured":"Zhang, Y. et al. Fecal microbiota transplantation promotes immunotherapy sensitivity in refractory gastrointestinal cancer patients: open label, single-arm, single center, phase 1 study. medRxiv https:\/\/doi.org\/10.1101\/2024.08.21.24312340 (2024).","journal-title":"medRxiv"},{"issue":"10","key":"44743_CR82","doi-asserted-by":"publisher","first-page":"S262","DOI":"10.1016\/j.jtho.2024.09.472","volume":"19","author":"MJ Huang","year":"2024","unstructured":"Huang, M. J. et al. P2.11A.23 Fecal microbiota transplantation plus rechallenging immunotherapy in patients with advanced non small cell lung cancer: An exploratory study. J. Thorac. Oncol. 19(10), S262\u2013S3. https:\/\/doi.org\/10.1016\/j.jtho.2024.09.472 (2024).","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"44743_CR83","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-025-03604-9","volume":"25","author":"X Wang","year":"2025","unstructured":"Wang, X. et al. Effect of probiotics combined with immune checkpoint suppressors and chemotherapeutic agents on digestive system function, intestinal immunity and prognosis in patients with metastatic colorectal carcinoma: A quasi-experimental study. BMC Gastroenterol. 25(1), 38. https:\/\/doi.org\/10.1186\/s12876-025-03604-9 (2025).","journal-title":"BMC Gastroenterol."},{"issue":"1","key":"44743_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-66449-0","volume":"10","author":"S Kim","year":"2020","unstructured":"Kim, S., Kim, A., Shin, J.-Y. & Seo, J.-S. The tumor immune microenvironmental analysis of 2,033 transcriptomes across 7 cancer types. Sci. Rep. 10(1), 9536. https:\/\/doi.org\/10.1038\/s41598-020-66449-0 (2020).","journal-title":"Sci. Rep."},{"key":"44743_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2021.634897","volume":"8","author":"Y Liu","year":"2022","unstructured":"Liu, Y., Wang, J. & Wu, C. Modulation of gut microbiota and immune system by probiotics, pre-biotics, and post-biotics. Front. Nutr. 8, 2021. https:\/\/doi.org\/10.3389\/fnut.2021.634897 (2022).","journal-title":"Front. Nutr."},{"key":"44743_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.562315","volume":"11","author":"S Chen","year":"2021","unstructured":"Chen, S. et al. Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis. Front. Oncol. 11, 562315. https:\/\/doi.org\/10.3389\/fonc.2021.562315 (2021).","journal-title":"Front. Oncol."},{"issue":"5","key":"44743_CR87","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1001\/jamaoncol.2023.7333","volume":"10","author":"A Mangla","year":"2024","unstructured":"Mangla, A. et al. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis. JAMA Oncol. 10 (5), 612\u2013620. https:\/\/doi.org\/10.1001\/jamaoncol.2023.7333 (2024).","journal-title":"JAMA Oncol."},{"issue":"9","key":"44743_CR88","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.3390\/cancers17091408","volume":"17","author":"V Mc Neil","year":"2025","unstructured":"Mc Neil, V. & Lee, S. W. Advancing Cancer Treatment: A Review of Immune Checkpoint Inhibitors and Combination Strategies. Cancers 17 (9), 1408 (2025). https:\/\/www.mdpi.com\/2072-6694\/17\/9\/1408","journal-title":"Cancers"},{"issue":"1","key":"44743_CR89","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s43046-025-00319-6","volume":"37","author":"M Devaraji","year":"2025","unstructured":"Devaraji, M. & Varghese Cheriyan, B. Immune-based cancer therapies: mechanistic insights, clinical progress, and future directions. J. Egypt. Natl Cancer Inst. 37 (1), 62. https:\/\/doi.org\/10.1186\/s43046-025-00319-6 (2025).","journal-title":"J. Egypt. Natl Cancer Inst."},{"issue":"1","key":"44743_CR90","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-024-02212-7","volume":"24","author":"BH Alsaafeen","year":"2025","unstructured":"Alsaafeen, B. H., Ali, B. R. & Elkord, E. Resistance mechanisms to immune checkpoint inhibitors: updated insights. Mol. Cancer. 24 (1), 20. https:\/\/doi.org\/10.1186\/s12943-024-02212-7 (2025).","journal-title":"Mol. Cancer"},{"key":"44743_CR91","doi-asserted-by":"publisher","first-page":"175883592110458","DOI":"10.1177\/17588359211045853","volume":"13","author":"EN Baruch","year":"2021","unstructured":"Baruch, E. N., Gaglani, T. & Wargo, J. A. Fecal microbiota transplantation as a mean of overcoming immunotherapy-resistant cancers - hype or hope? Ther. Adv. Med. Oncol. 13, 17588359211045853. https:\/\/doi.org\/10.1177\/17588359211045853 (2021).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"44743_CR92","doi-asserted-by":"publisher","first-page":"104967","DOI":"10.1016\/j.ebiom.2024.104967","volume":"100","author":"Y Yang","year":"2024","unstructured":"Yang, Y. et al. Fecal microbiota transplantation: no longer cinderella in tumour immunotherapy. eBioMedicine 100, 104967. https:\/\/doi.org\/10.1016\/j.ebiom.2024.104967 (2024).","journal-title":"eBioMedicine"},{"issue":"2","key":"44743_CR93","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.molonc.2012.01.011","volume":"6","author":"M De Palma","year":"2012","unstructured":"De Palma, M. & Hanahan, D. The biology of personalized cancer medicine: Facing individual complexities underlying hallmark capabilities. Mol. Oncol. 6 (2), 111\u2013127. https:\/\/doi.org\/10.1016\/j.molonc.2012.01.011 (2012).","journal-title":"Mol. Oncol."},{"key":"44743_CR94","doi-asserted-by":"publisher","first-page":"937874","DOI":"10.3389\/fphar.2022.937874","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. The correlation between probiotic use and outcomes of cancer patients treated with immune checkpoint inhibitors. Front. Pharmacol. 13, 937874. https:\/\/doi.org\/10.3389\/fphar.2022.937874 (2022).","journal-title":"Front. Pharmacol."},{"key":"44743_CR95","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.544490","volume":"11","author":"VL Batista","year":"2020","unstructured":"Batista, V. L. et al. Probiotics, prebiotics, synbiotics, and paraprobiotics as a therapeutic alternative for intestinal mucositis. Front. Microbiol. 11, 2020. https:\/\/doi.org\/10.3389\/fmicb.2020.544490 (2020).","journal-title":"Front. Microbiol."},{"issue":"13_Supplement","key":"44743_CR96","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1538-7445.Am2019-2838","volume":"79","author":"CN Spencer","year":"2019","unstructured":"Spencer, C. N. et al. Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors. Cancer Res. 79 (13_Supplement), 2838. https:\/\/doi.org\/10.1158\/1538-7445.Am2019-2838 (2019).","journal-title":"Cancer Res."},{"issue":"7","key":"44743_CR97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0307639","volume":"19","author":"SM Ajab","year":"2024","unstructured":"Ajab, S. M. et al. Microbiota composition effect on immunotherapy outcomes in colorectal cancer patients: A systematic review. PLoS. One 19(7), e0307639. https:\/\/doi.org\/10.1371\/journal.pone.0307639 (2024).","journal-title":"PLoS. One"},{"issue":"4","key":"44743_CR98","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101478","volume":"5","author":"X Kang","year":"2024","unstructured":"Kang, X., Lau, H. C. & Yu, J. Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy. Cell Rep. Med. 5(4), 101478. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101478 (2024).","journal-title":"Cell Rep. Med."},{"issue":"1","key":"44743_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-025-00786-8","volume":"11","author":"W Lei","year":"2025","unstructured":"Lei, W., Zhou, K., Lei, Y., Li, Q. & Zhu, H. Gut microbiota shapes cancer immunotherapy responses. Npj. Biofilms Microbiomes 11(1), 143. https:\/\/doi.org\/10.1038\/s41522-025-00786-8 (2025).","journal-title":"Npj. Biofilms Microbiomes"},{"issue":"1","key":"44743_CR100","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-025-00678-x","volume":"11","author":"J Sun","year":"2025","unstructured":"Sun, J. et al. Gut microbiota as a new target for anticancer therapy: From mechanism to means of regulation. Npj. Biofilms Microbiomes 11(1), 43. https:\/\/doi.org\/10.1038\/s41522-025-00678-x (2025).","journal-title":"Npj. Biofilms Microbiomes"},{"issue":"1","key":"44743_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41522-025-00646-5","volume":"11","author":"Q Xu","year":"2025","unstructured":"Xu, Q. et al. The oral-gut microbiota axis: A link in cardiometabolic diseases. Npj. Biofilms Microbiomes 11(1), 11. https:\/\/doi.org\/10.1038\/s41522-025-00646-5 (2025).","journal-title":"Npj. Biofilms Microbiomes"},{"issue":"3","key":"44743_CR102","doi-asserted-by":"publisher","first-page":"751S","DOI":"10.1093\/jn\/137.3.751S","volume":"137","author":"M Blaut","year":"2007","unstructured":"Blaut, M. & Clavel, T. Metabolic diversity of the intestinal microbiota: Implications for health and disease1,. J. Nutr. 137(3), 751S\u20135S. https:\/\/doi.org\/10.1093\/jn\/137.3.751S (2007).","journal-title":"J. Nutr."},{"key":"44743_CR103","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1518474","volume":"15","author":"Y Jin","year":"2025","unstructured":"Jin, Y., Jie, Z. & Fan, X. Gut microbes and immunotherapy for non-small cell lung cancer: A systematic review. Front. Oncol. 15, 2025. https:\/\/doi.org\/10.3389\/fonc.2025.1518474 (2025).","journal-title":"Front. Oncol."},{"key":"44743_CR104","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1512683","volume":"15","author":"MY Lim","year":"2025","unstructured":"Lim, M. Y., Hong, S. & Nam, Y.-D. Understanding the role of the gut microbiome in solid tumor responses to immune checkpoint inhibitors for personalized therapeutic strategies: A review. Front. Immunol. 15, 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1512683 (2025).","journal-title":"Front. Immunol."},{"issue":"1","key":"44743_CR105","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41416-024-02887-1","volume":"132","author":"B Jayathilaka","year":"2025","unstructured":"Jayathilaka, B., Mian, F., Franchini, F., Au-Yeung, G. & Ijzerman, M. Cancer and treatment specific incidence rates of immune-related adverse events induced by immune checkpoint inhibitors: A systematic review. Br. J. Cancer. 132(1), 51\u201357. https:\/\/doi.org\/10.1038\/s41416-024-02887-1 (2025).","journal-title":"Br. J. Cancer."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44743-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44743-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44743-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:34:23Z","timestamp":1777505663000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-44743-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,17]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["44743"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-44743-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,17]]},"assertion":[{"value":"17 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13859"}}